Form 4: Novavax Executive Filip Dubovsky Reports Stock Transactions
SEC Form 4 Filing
Filip Dubovsky, President of R&D at Novavax, reported the vesting and subsequent disposal of shares related to restricted stock units.
Summary
- On March 7, 2024, Filip Dubovsky, President of R&D at Novavax, reported transactions involving Novavax common stock.
- These transactions involved the vesting of 19,444 restricted stock units (RSUs) and the disposal of 9,392 shares to cover tax obligations at a price of $5.61 per share.
- Following these transactions, Dubovsky directly owns 63,834 shares of Novavax common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which is important for investors to gauge management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect insider trading activity related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 03/07/2023 | Grant date of the restricted stock units, vesting in three annual installments. |
| 03/07/2024 | Date of the reported transactions: vesting of RSUs and disposal of shares. |
| 03/11/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.